NewLink Genetics to Participate in Baird Healthcare Conference
September 01 2016 - 7:00AM
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical
company focused on bringing novel immuno-oncology therapies to
patients with cancer, today announced that it will participate in
the Baird Healthcare Conference in New York.
The presentation is at 4:20 p.m. ET on
Wednesday, September 7, 2016.
A live webcast of the presentation will be available on the
Company's website at www.newlinkgenetics.com in the "Investors
& Media" section under "Events and Presentations."
About NewLink Genetics
Corporation
NewLink Genetics is a biopharmaceutical company at the forefront
of discovering, developing and commercializing novel
immuno-oncology product candidates to improve the lives of patients
with cancer. NewLink Genetics’ portfolio includes biologic and
small molecule immunotherapy product candidates intended to treat a
wide range of oncology indications. NewLink Genetics’ product
candidates are designed to harness multiple components of the
immune system to combat cancer. For more information, please
visit http://www.newlinkgenetics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements of NewLink Genetics that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, contained in this press release are forward-looking
statements, within the meaning of The Private Securities Litigation
Reform Act of 1995. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “target,” “potential,” “will,”
“could,” “should,” “seek” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include
any statements other than statements of historical fact. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that NewLink Genetics makes due to a number of important
factors, including those risks discussed in “Risk Factors” and
elsewhere in NewLink Genetics’ Annual Report on Form 10-K for the
year ended December 31, 2015 and other reports filed with the U.S.
Securities and Exchange Commission (SEC). The forward-looking
statements in this press release represent NewLink' Genetics’ views
as of the date of this press release. NewLink Genetics anticipates
that subsequent events and developments will cause its views to
change. However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink Genetics’ views
as of any date subsequent to the date of this press release.
Corporate Contact:
Jack Henneman
Chief Financial Officer
(515) 598-2561
Investor@linkp.com
Media & Investor Contact:
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
bkurth@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Aug 2024 to Sep 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Sep 2023 to Sep 2024